paras_biotech
@paras-sharma.bsky.social
In Life Science Venture Capital @ Genesys Capital
- LoQus23 raised $43M for allosteric small molecule inhibitor of MutSβ
- Uniqure disclosed Phase1/2 AMT-130 showing - disease slow by about 80% compared to a natural history
- Roche paied $60M upfront to Ionis 2 pre-clinical assets
- Uniqure disclosed Phase1/2 AMT-130 showing - disease slow by about 80% compared to a natural history
- Roche paied $60M upfront to Ionis 2 pre-clinical assets
December 7, 2024 at 9:56 PM
- LoQus23 raised $43M for allosteric small molecule inhibitor of MutSβ
- Uniqure disclosed Phase1/2 AMT-130 showing - disease slow by about 80% compared to a natural history
- Roche paied $60M upfront to Ionis 2 pre-clinical assets
- Uniqure disclosed Phase1/2 AMT-130 showing - disease slow by about 80% compared to a natural history
- Roche paied $60M upfront to Ionis 2 pre-clinical assets
Recent news in HD space -
- Novartis paid $1B upfront to access PTCT's Phase2 staged silicing modulator
- Sage's GABAA receptor modulator Phase 2 drug failed
- Takeda discontinued its collab with Wave's allele-selective antisense oligonucleotide
- Novartis paid $1B upfront to access PTCT's Phase2 staged silicing modulator
- Sage's GABAA receptor modulator Phase 2 drug failed
- Takeda discontinued its collab with Wave's allele-selective antisense oligonucleotide
December 7, 2024 at 9:56 PM
Recent news in HD space -
- Novartis paid $1B upfront to access PTCT's Phase2 staged silicing modulator
- Sage's GABAA receptor modulator Phase 2 drug failed
- Takeda discontinued its collab with Wave's allele-selective antisense oligonucleotide
- Novartis paid $1B upfront to access PTCT's Phase2 staged silicing modulator
- Sage's GABAA receptor modulator Phase 2 drug failed
- Takeda discontinued its collab with Wave's allele-selective antisense oligonucleotide
Total Addressable Market For Cell Therapy/Bispecifics
November 25, 2024 at 2:35 AM
Total Addressable Market For Cell Therapy/Bispecifics